₹568.20
−0.83%NSE close, 16 Nov 2026
−25.20%
Healthcare Global Enterprises is a small cap company in the Healthcare sector, listed on NSE under the symbol HCG. At ₹568.20 a share, the market values the whole company at ₹8,483 crore.
In FY26, it reported sales of ₹2,545 crore and a net profit of ₹14 crore, an operating margin of 18.3%. Over the last three years, sales grew 14.5% a year and net profit fell 22.3% a year.
The market values the company at 750.7 times its profit over the last twelve months and 6.29 times its book value; its return on equity is 0.8% and its borrowings are 0.55 times its equity.
Promoters hold 64.21% of the shares, and have pledged 5.2% of their holding. Foreign institutions hold 2.69%, and domestic institutions, mutual funds among them, 20.77%.
Over the past year the share price has fallen 24.8%, and it is 26.7% below its 52-week high.
Companies of a similar size in the same sector include Viyash Scientific, Yatharth Hospital & Trauma Care Services, Blue Jet Healthcare and Procter & Gamble Health.
₹ crore. Consolidated figures.
The same sector (Healthcare), nearest in size.
| Company | Price | Market cap | P/E | ROE | Sales growth | 1Y |
|---|---|---|---|---|---|---|
| Healthcare Global Enterprises | ₹568.20 | ₹8,483 cr | 750.7 | 0.8% | +13.10% | −24.77% |
| Viyash Scientific | ₹236.38 | ₹10,439 cr | 44.9 | 7.3% | +133.00% | +9.21% |
| Yatharth Hospital & Trauma Care Services | ₹1,069.05 | ₹10,301 cr | 54.9 | 10.0% | +54.40% | +34.65% |
| Blue Jet Healthcare | ₹512.95 | ₹9,709 cr | 34.0 | 12.4% | +127.10% | −8.67% |
| Procter & Gamble Health | ₹5,595.50 | ₹9,288 cr | 24.5 |
Transcript of the Earnings Call held with Analysts/Investors on November 06, 2026 to discuss the Unaudited Financial Results of the Company for the quarter and six months ended September 30, 2026
Link of Recording
A press release dated November 05, 2026 on the unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter and six months ended September 30, 2026.
Written from the company's filings with NSE and the exchanges' daily prices. For information only, not a recommendation to buy, sell or hold any security.
| Mar 2026 |
|---|
| Jun 2026 |
|---|
| Sep 2026 |
|---|
| Sales | 470 | 495 | 526 | 554 | 558 | 585 | 613 | 647 | 633 | 652 | 695 | 732 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Expenses | 391 | 403 | 435 | 451 | 470 | 479 | 505 | 524 | 523 | 527 | 573 | 598 |
| Operating profit | 78.6 | 92.0 | 90.9 | 102 | 87.4 | 106 | 108 | 123 | 110 | 125 | 122 | 133 |
| Operating margin | 16.7% | 18.6% | 17.3% | 18.5% | 15.7% | 18.1% | 17.6% | 19.1% | 17.3% | 19.2% | 17.6% | 18.2% |
| Other income | 6.1 | 5.1 | 8.8 | 11.1 | 5.7 | 10.2 | 6.8 | 2.6 | 2.5 | 13.1 | 12.1 | 1.9 |
| Interest | 29.5 | 26.8 | 33.7 | 36.0 | 40.7 | 44.2 | 45.5 | 43.6 | 44.8 | 42.7 | 39.9 | 38.4 |
| Depreciation | 44.2 | 46.0 | 47.0 | 49.7 | 56.5 | 58.1 | 57.9 | 62.8 | 60.7 | 62.8 | 70.4 | 67.8 |
| Profit before tax | 11.1 | 28.2 | 19.0 | 27.7 | −4.2 | 13.7 | 11.2 | 19.5 | −6.0 | 0.7 | 24.1 | 17.5 |
| Tax | 7.6 | 4.8 | 5.4 | 7.0 | −11.1 | 6.9 | 5.9 | −0.8 | 1.8 | −2.8 | 8.6 | 9.2 |
| Net profit | 5.7 | 21.3 | 12.1 | 18.0 | 7.0 | 7.4 | 4.8 | 16.3 | −9.4 | 2.2 | 13.8 | 4.8 |
| EPS (₹) | 0.41 | 1.53 | 0.87 | 1.29 | 0.50 | 0.53 | 0.34 | 1.16 | -0.68 | 0.15 | 0.92 | 0.32 |
₹ crore, financial years to March.
| Line | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Sales | 976 | 1,096 | 1,013 | 1,398 | 1,694 | 1,912 | 2,223 | 2,545 |
| Expenses | 853 | 923 | 887 | 1,160 | 1,396 | 1,583 | 1,836 | 2,080 |
| Operating profit | 123 | 172 | 127 | 238 | 299 | 330 | 387 | 466 |
| Operating margin | 12.6% | 15.7% | 12.5% | 17.0% | 17.6% | 17.2% | 17.4% | 18.3% |
| Other income | 10.1 | 7.0 | 17.0 | 12.7 | 13.2 | 16.9 | 34.8 | 25.0 |
| Interest | 69.9 | 138 | 119 | 97.8 | 104 | 109 | 155 | 177 |
| Depreciation | 85.1 | 148 | 159 | 158 | 163 | 174 | 211 | 244 |
| Profit before tax | −22.4 | −107 | −228 | 89.2 | 44.9 | 67.3 | 56.2 | 25.5 |
| Tax | −2.5 | 6.2 | −7.6 | 48.9 | 27.3 | 26.4 | 8.1 | 4.1 |
| Net profit | −24.8 | −107 | −193 | 53.7 | 29.3 | 48.1 | 44.4 | 13.8 |
| EPS (₹) | -2.82 | -12.05 | -17.02 | 4.14 | 2.11 | 3.47 | 3.19 | 0.97 |
₹ crore, at each year's end and the latest half year.
| Line | FY23 | FY24 | FY25 | FY26 | Sep 2026 |
|---|---|---|---|---|---|
| Shareholders’ equity | 861 | 826 | 922 | 1,332 | 1,349 |
| Borrowings | 399 | 673 | 1,002 | 910 | 742 |
| Total liabilities | 1,447 | 1,842 | 2,553 | 2,512 | 2,296 |
| Fixed assets | 1,353 | 1,505 | 1,963 | 2,041 | 2,166 |
| Investments | 6.8 | 7.0 | 7.0 | 7.1 | 7.5 |
| Cash and equivalents | 175 | 273 | 236 | 536 | 120 |
| Total assets | 2,316 | 2,708 | 3,543 | 3,923 | 3,730 |
₹ crore, by financial year, and the latest half year.
| Line | FY22 | FY25 | FY26 | 6M to Sep 2026 |
|---|---|---|---|---|
| From operations | 220 | 317 | 347 | 139 |
| From investing | 125 | −488 | −177 | −270 |
| From financing | −155 | −42.4 | 241 | −225 |
| Spent on fixed assets | −71.2 | −209 | −292 | −130 |
| Free cash flow | 149 | 108 | 55.0 | 8.8 |
Margins, returns, debt, tax and cash.
| Line | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Net margin | -2.5% | -9.7% | -19.1% | 3.8% | 1.7% | 2.5% | 2.0% | 0.5% |
| Operating margin | 12.6% | 15.7% | 12.5% | 17.0% | 17.6% | 17.2% | 17.4% | 18.3% |
| Return on equity | – | – | – | – | 3.4% | 5.8% | 4.8% | 1.0% |
| Return on capital employed | – | – | – | – | 11.8% | 11.7% | 10.9% | 9.0% |
| Return on assets | – | – | – | – | 1.3% | 1.8% | 1.3% | 0.4% |
| Debt to equity | – | – | – | – | 0.46 | 0.81 | 1.09 | 0.68 |
| Interest coverage | 0.70 | 0.20 | -0.90 | 1.90 | 1.40 | 1.60 | 1.40 | 1.10 |
| Debt to assets | – | – | – | – | 0.17 | 0.25 | 0.28 | 0.23 |
| Current ratio | – | – | – | – | 1.02 | 0.91 | 0.81 | 1.09 |
| Quick ratio | – | – | – | – | 0.95 | 0.86 | 0.76 | 1.03 |
| Cash ratio | – | – | – | – | 0.31 | 0.37 | 0.23 | 0.55 |
| Asset turnover | – | – | – | – | 0.73 | 0.71 | 0.63 | 0.65 |
| Fixed asset turnover | – | – | – | – | 1.25 | 1.27 | 1.13 | 1.25 |
| Inventory turnover | – | – | – | – | – | 11.10 | 11.00 | 11.60 |
| Receivables turnover | – | – | – | – | 5.60 | 6.50 | 5.50 | 6.10 |
| Gross margin | – | – | – | – | – | 75.1% | 73.9% | 72.8% |
| Cash from operations to profit | – | – | – | 410.0% | – | – | 714.0% | 2,523.0% |
| Effective tax rate | – | – | – | 54.8% | 60.7% | 39.2% | 14.5% | 16.3% |
| 57.7% |
| +17.70% |
| −6.69% |
| Strides Pharma Science | ₹986.10 | ₹9,089 cr | 14.7 | 18.1% | +17.10% | +2.78% |
|---|
| Aarti Pharmalabs | ₹986.75 | ₹8,948 cr | 35.4 | 11.2% | +45.90% | +16.93% |
|---|
| Thyrocare Technologies | ₹509.65 | ₹8,112 cr | 56.3 | 26.1% | +25.10% | +15.46% |
|---|
| Suven Life Sciences | ₹268.90 | ₹7,598 cr | n/a | -84.2% | +30.40% | +39.45% |
|---|
The Nomination and Remuneration Committee of the Board of Directors of the Company, at its meeting held today, i.e., November 05, 2026, has approved grant of Employee Stock Options to the eligible employees of the Company and its subsidiary company(ies) and associate…
Unaudited Financial Results of the Company (Standalone and Consolidated), for the quarter and six months ended September 30, 2026.
Earnings Call to discuss the Unaudited Financial Results of the Company.
Has informed that Healthcare Global (Kenya) Private Limited ( HCG Kenya ), a step-down subsidiary of Healthcare Global Enterprises Limited ( Company ), has today, i.e., October 05, 2026, entered into a Share Purchase Agreement ( SPA ) with Meditec Systems Limited ( Meditec )…
A copy Srutinizers report of Annual General Meeting held on September 18, 2026. Further, the company has informed the Exchange regarding voting results.
Proceedings of Annual General Meeting held on September 18, 2026
Schedule of meet
Grant of Employee Stock Options under HealthCare Global Enterprises Limited- Employee Stock Option Scheme, 2026
Letter to Members of the Company containing weblink and path of Integrated Annual Report for the Financial Year 2025-26.
Notice of Annual General Meeting to be held on September 18, 2026 and Annual Report for FY 2025-26
Business Responsibility and Sustainability Report' for FY 2026.